Caramedica Pharmaceuticals

Karamedica is a biotechnology company focused on expanding the medical and veterinary applications of chitosan-based biopolymers. The company utilizes a proprietary non-thermal atmospheric pressure nitrogen plasma technology to decontaminate delicate biomaterials without damaging their biological properties. Karamedica's lead programs include a microparticle therapy for cerebral amyloid angiopathy (CAA) delivered intranasally and a chitosan-hydrogel immunotherapy for superficial bladder cancer. Additionally, the company is developing resorbable hemostatic devices for surgical use. By overcoming the sterilization barriers that have historically limited the clinical use of chitosan, Karamedica aims to enable a wide range of implantable and injectable therapeutics.